155 related articles for article (PubMed ID: 31945198)
1. Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data.
Zhu R; Wang Z; Hu Y
Clin Endocrinol (Oxf); 2020 Apr; 92(4):295-302. PubMed ID: 31945198
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
3. THE INFLUENCE OF SURGICAL EXTENT AND PARAFIBROMIN STAINING ON THE OUTCOME OF PARATHYROID CARCINOMA: 20-YEAR EXPERIENCE FROM A SINGLE INSTITUTE.
Hu Y; Bi Y; Cui M; Zhang X; Su Z; Wang M; Hua S; Liao Q; Zhao Y
Endocr Pract; 2019 Jul; 25(7):634-641. PubMed ID: 30865538
[No Abstract] [Full Text] [Related]
4. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
[TBL] [Abstract][Full Text] [Related]
5. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
[TBL] [Abstract][Full Text] [Related]
6. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
Cetani F; Banti C; Pardi E; Borsari S; Viacava P; Miccoli P; Torregrossa L; Basolo F; Pelizzo MR; Rugge M; Pennelli G; Gasparri G; Papotti M; Volante M; Vignali E; Saponaro F; Marcocci C
Endocr Connect; 2013; 2(4):186-95. PubMed ID: 24145611
[TBL] [Abstract][Full Text] [Related]
7. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
[TBL] [Abstract][Full Text] [Related]
8. [CDC73 gene mutation and parafibromin expression status of parathyroid carcinoma in Chinese].
Kong J; Wang O; Nie M; Shi J; Jiang Y; Li M; Xia WB; Meng XW; Xing XP
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(42):3364-8. PubMed ID: 24418033
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis.
Hu Y; Liao Q; Cao S; Gao X; Zhao Y
Endocrine; 2016 Dec; 54(3):612-619. PubMed ID: 27250989
[TBL] [Abstract][Full Text] [Related]
11. Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of
Gheorghe AM; Sima OC; Florescu AF; Ciuche A; Nistor C; Sandru F; Carsote M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396977
[TBL] [Abstract][Full Text] [Related]
12. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
[TBL] [Abstract][Full Text] [Related]
13. Genotype of CDC73 germline mutation determines risk of parathyroid cancer.
Li Y; Zhang J; Adikaram PR; Welch J; Guan B; Weinstein LS; Chen H; Simonds WF
Endocr Relat Cancer; 2020 Sep; 27(9):483-494. PubMed ID: 32590342
[TBL] [Abstract][Full Text] [Related]
14. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
15. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
[TBL] [Abstract][Full Text] [Related]
17. Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature.
Popow M; Kaszczewska M; Góralska M; Kaszczewski P; Skwarek-Szewczyk A; Chudziński W; Jażdżewski K; Kolanowska M; Bogdańska M; Starzyńska-Kubicka A; Gałązka Z
Am J Case Rep; 2022 Oct; 23():e936135. PubMed ID: 36271606
[TBL] [Abstract][Full Text] [Related]
18. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic significance of parafibromin expression in parathyroid carcinoma.
Gao Y; Wang P; Lu J; Pan B; Guo D; Zhang Z; Wang A; Zhang M; Sun J; Wang W; Liang Z
Hum Pathol; 2022 Sep; 127():28-38. PubMed ID: 35654240
[TBL] [Abstract][Full Text] [Related]
20. The genomic profile of parathyroid carcinoma based on whole-genome sequencing.
Hu Y; Zhang X; Wang O; Bi Y; Xing X; Cui M; Wang M; Tao W; Liao Q; Zhao Y
Int J Cancer; 2020 Nov; 147(9):2446-2457. PubMed ID: 32574388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
